HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- dimethylamino- 4,5,6,7- tetrabromo- 1H- benzimidazole

a protein kinase CK2 inhibitor; structure in first source

Also Known As:

4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzimidazole; DMAT cpd

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: 6

Experts

1.	Kazimierczuk, Zygmunt: 3 articles (11/2013 - 11/2009)
2.	Ahmed, Khalil: 2 articles (01/2014 - 02/2012)
3.	Korman, Vicci L: 2 articles (01/2014 - 02/2012)
4.	Kren, Betsy T: 2 articles (01/2014 - 02/2012)
5.	Trembley, Janeen H: 2 articles (01/2014 - 02/2012)
6.	Unger, Gretchen M: 2 articles (01/2014 - 02/2012)
7.	Abedin, J: 1 article (01/2014)
8.	Gomez, Omar Cespedes: 1 article (01/2014)
9.	Niehans, Gloria: 1 article (01/2014)
10.	Vogel, Rachel I: 1 article (01/2014)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/01/2013 - "In this study, we examined pro-apoptotic and cytostatic effects of three CK2 inhibitors: one known, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) and two new: 2-(4-methylpiperazin-1-yl)-4,5,6,7-tetrabromo-1H-benzimidazole (MPT) and 2-aminoethyleneamino-4,5,6,7-tetrabromo-1H-benzimidazole (AEAT), as well as of certain S-2,3,4,5,6-pentabromobenzylisothiouronium bromides: ZKK-3, ZKK-9, ZKK-13, against the human acute myelogenous leukemia cell line (KG-1). "
2.	Prostatic Neoplasms (Prostate Cancer) 01/01/2014 - "We previously reported on the malignant cell specificity and effect on CK2 signaling of a tenfibgen (TBG) based nanocapsule for delivery of the CK2 small molecule inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) in cultured prostate cancer cells. " 02/01/2012 - "We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. "
3.	Neoplasms (Cancer) 11/01/2011 - "COX-2 expression and cell viability decreased upon selective inhibition of COX-2 with SC-791 or CK2 with 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), both in human colon (HT29-ATCC, HT29-US, DLD-1) and breast (ZR-75) cancer cells, as well as in human embryonic kidney (HEK-293T) cells. "
4.	Glioma (Gliomas) 11/01/2009 - "Here we compared cytotoxic effects of well-known and new CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBB), 4,5,6,7-tetrabromo-1H-benzimidazole (TBI), 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), the related 3-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)propan-1-ol (MB001), 3-(4,5,6,7-tetrabromo-1H-1,2,3-benzotriazol-1-yl) propan-1-ol (MB002), 3-(4,5,6,7-tetrabromo-2H-1,2,3-benzotriazol-2-yl)propan-1-ol (MB003) and also structurally similar to above compounds pentabromobenzylisothiourea (ZKK1) and its derivatives (ZKK2-8) on cultured malignant glioma cells. "
5.	Colonic Neoplasms (Colon Cancer) 10/10/2006 - "TBB and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole significantly decreased proliferation and increased apoptosis of HT29(US) colon cancer cells. "

Related Drugs and Biologics

1.	Cytostatic Agents
2.	Bromides
3.	ZKK-13
4.	Nanocapsules
5.	tenfibgen
6.	Small Interfering RNA (siRNA)
7.	SC 791